Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5705)
All Articles published online
|
Feb 28, 2012 (publication date) through Feb 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i8/736.htm |
| Number | Citing Articles |
| 1 |
Kolaparthi Venkatasubbarao, Lindsay Peterson, Shujie Zhao, Ping Hill, Lin Cao, Qing Zhou, Steffan T Nawrocki, James W Freeman. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-104
|
| 2 |
P.T.P. Kaumaya, T. Bekaii-Saab. Comprehensive Medicinal Chemistry III. 2017; : 1 doi: 10.1016/B978-0-12-409547-2.12422-9
|
| 3 |
Mert Erkan, Tania Brocks, Helmut Friess. Cancer Targeted Drug Delivery. 2013; : 309 doi: 10.1007/978-1-4614-7876-8_12
|
| 4 |
Daniela L. Papademetrio, María Noé Garcia, Daniel Grasso, Élida Alvarez. Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer Microenvironment. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.622956
|
| 5 |
Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Yi Zhang, Hongyan Zhu, Tianqing Liu. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. Pharmaceutics 2021; 13(9): 1493 doi: 10.3390/pharmaceutics13091493
|
| 6 |
Yun Wang, Liankang Sun, Yumei Luo, Shuixiang He. Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells. Pathology - Research and Practice 2019; 215(5): 1054 doi: 10.1016/j.prp.2019.02.014
|
| 7 |
Nilanjana Tewari, Abed M Zaitoun, Arvind Arora, Srinivasan Madhusudan, Mohammad Ilyas, Dileep N Lobo. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-436
|
| 8 |
Lei Tan, Xiaohua Duan, Pratyusha Mutyala, Ting Zhou, Sadaf Amin, Tuo Zhang, Brian Herbst, Gokce Askan, Tomer Itkin, Zhaoying Xiang, Fabrizio Michelassi, Michael D Lieberman, Christine A Iacobuzio-Donahue, Steven D Leach, Todd Evans, Shuibing Chen, Hua Lu. A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells. Journal of Molecular Cell Biology 2023; 15(6) doi: 10.1093/jmcb/mjad039
|
| 9 |
Xiong Zhang, Fen-Shu Jin, Li-Guo Zhang, Rui-Xue Chen, Jin-Hui Zhao, Yan-Nan Wang, En-Fu Wang, Zhen-Dong Jiang. Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis. Asian Pacific Journal of Cancer Prevention 2013; 14(7): 4261 doi: 10.7314/APJCP.2013.14.7.4261
|
| 10 |
Divya Thomas, Prakash Radhakrishnan. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Molecular Cancer 2019; 18(1) doi: 10.1186/s12943-018-0927-5
|
| 11 |
Tianjiao Wang, Zhumei Zhuang, Peng Zhang, Yueyue Wang, Lin Mu, Haifeng Jin, Lei Zhou, Xiaochi Ma, Rui Liang, Yuhui Yuan. Effect of arenobufagin on human pancreatic carcinoma cells. Oncology Letters 2017; 14(4): 4971 doi: 10.3892/ol.2017.6798
|
| 12 |
Arnav Bhattacharya, Anirudh Santhoshkumar, Hiroshi Kurahara, Sitaram Harihar. Metastasis Suppressor Genes in Pancreatic Cancer. Pancreas 2021; 50(7): 923 doi: 10.1097/MPA.0000000000001853
|
| 13 |
Loganayaki Periyasamy, Bharathi Muruganantham, Woo-Yoon Park, Sridhar Muthusami. Phyto-targeting the CEMIP Expression as a Strategy to Prevent Pancreatic Cancer Metastasis. Current Pharmaceutical Design 2022; 28(11): 922 doi: 10.2174/1381612828666220302153201
|
| 14 |
Wen Shi, Sunny M. Ogbomo, Nilesh K. Wagh, Zhengyuan Zhou, Yinnong Jia, Susan K. Brusnahan, Jered C. Garrison. The influence of linker length on the properties of cathepsin S cleavable 177Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials 2014; 35(22): 5760 doi: 10.1016/j.biomaterials.2014.03.056
|
| 15 |
Qingxi Yue, Guogang Gao, Gangyong Zou, Haiqing Yu, Xi Zheng. Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/8412508
|
| 16 |
Gerardo G Mackenzie, Lauren E Bartels, Gang Xie, Ioannis Papayannis, Ninche Alston, Kvetoslava Vrankova, Nengtai Ouyang, Basil Rigas. A Novel Ras Inhibitor (MDC-1016) Reduces Human Pancreatic Tumor Growth in Mice. Neoplasia 2013; 15(10): 1184 doi: 10.1593/neo.131368
|
| 17 |
Domenico Ciliberto, Cirino Botta, Pierpaolo Correale, Marco Rossi, Michele Caraglia, Pierfrancesco Tassone, Pierosandro Tagliaferri. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer 2013; 49(3): 593 doi: 10.1016/j.ejca.2012.08.019
|
| 18 |
Hong He, Hiroshi Maruta. Paks, Rac/Cdc42 (p21)-activated Kinases. 2013; : 23 doi: 10.1016/B978-0-12-407198-8.00002-3
|
| 19 |
Qiu‐Rui He, Jiang‐Jiang Tang, Yao Liu, Zhi‐Fan Chen, Yu‐Xi Liu, Huang Chen, Ding Li, Zheng‐Fang Yi, Jin‐Ming Gao. The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. British Journal of Pharmacology 2021; 178(12): 2496 doi: 10.1111/bph.15435
|
| 20 |
Joseph Markowitz, Taylor R. Brooks, Megan C. Duggan, Bonnie K. Paul, Xueliang Pan, Lai Wei, Zachary Abrams, Eric Luedke, Gregory B. Lesinski, Bethany Mundy-Bosse, Tanios Bekaii-Saab, William E. Carson. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunology, Immunotherapy 2015; 64(2): 149 doi: 10.1007/s00262-014-1618-8
|
| 21 |
De-Jun Liu, Yue-Xia Xie, Xiao-Xing Liu, Yan-Miao Huo, Min-Wei Yang, Xue-Liang Fu, Wei Liu, Jian-Yu Yang, Jiao Li, Rong Hua, Pei-Feng Liu, Yong-Wei Sun, Jun-Feng Zhang. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Cell Cycle 2017; 16(17): 1622 doi: 10.1080/15384101.2017.1356510
|
| 22 |
Juan Du, Linxi Zhu, Huizi Sha, Zhengyun Zou, Jie Shen, Weiwei Kong, Lianjun Zhao, Qing Gu, Lixia Yu, Yudong Qiu, Baorui Liu. Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1015232
|
| 23 |
Minami Hashimoto, Takuto Hikichi, Tomohiro Suzuki, Mayumi Tai, Osamu Ichii, Nobuo Matsuhashi, Eisaku Kita, Shintaro Takahashi, Yoshinori Okubo, Hando Hakozaki, Yutaka Ejiri, Hiromasa Ohira. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. Clinical Journal of Gastroenterology 2017; 10(6): 564 doi: 10.1007/s12328-017-0785-5
|
| 24 |
Mingxia Lu, Yu‐Kai Wang, Jiacheng Zhao, Hongxu Lu, Martina H. Stenzel, Pu Xiao. PEG Grafted‐Nanodiamonds for the Delivery of Gemcitabine. Macromolecular Rapid Communications 2016; 37(24): 2023 doi: 10.1002/marc.201600344
|
| 25 |
Naveen A. Mallangada, Joselin M. Vargas, Swaroopa Thomas, Matthew G. DiGiovanni, Brandon M. Vaeth, Matthew D. Nemesure, Ruixue Wang, Joseph F. LaComb, Jennie L. Williams, Lorne M. Golub, Francis Johnson, Gerardo G. Mackenzie. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Molecular Carcinogenesis 2018; 57(9): 1130 doi: 10.1002/mc.22830
|
| 26 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Takaaki Arigami, Shinichiro Mori, Shinichi Ueno, Hiroyuki Shinchi, Sonshin Takao, Shoji Natsugoe. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology 2016; 16(6): 1051 doi: 10.1016/j.pan.2016.09.014
|
| 27 |
Efficacy and Safety of Fixed-Dose-Rate Infusions of Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer. Journal of Analytical Oncology 2015; 4(1) doi: 10.6000/1927-7229.2015.04.01.8
|
| 28 |
J. Al Shemaili, E. Mensah-Brown, K. Parekh, S.A. Thomas, S. Attoub, B. Hellman, F. Nyberg, A. Adem, P. Collin, T.E. Adrian. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer. European Journal of Cancer 2014; 50(7): 1391 doi: 10.1016/j.ejca.2014.01.002
|
| 29 |
Lauren A. Mauro, Joseph M. Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology. 2014; : 1397 doi: 10.1016/B978-1-4557-2865-7.00081-3
|
| 30 |
Libin Wang, Feng Wang, Li Na, Jingjing Yu, Liya Huang, Zhi-Qiang Meng, Zhen Chen, Hao Chen, Liu-Lu Ming, Yong-Qiang Hua. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma. Cancer Biomarkers 2018; 22(1): 169 doi: 10.3233/CBM-181182
|
| 31 |
Weiliang Jiang, Senlin Zhao, Ling Xu, Yingying Lu, Zhanjun Lu, Congying Chen, Jianbo Ni, Rong Wan, Lijuan Yang. The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancer. Biomedicine & Pharmacotherapy 2015; 73: 40 doi: 10.1016/j.biopha.2015.05.020
|
| 32 |
Brian Herbst, Lei Zheng. Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology & Hepatology 2019; 4(10): 805 doi: 10.1016/S2468-1253(19)30175-X
|
| 33 |
Violetta Krajka-Kuźniak, Marta Cykowiak, Hanna Szaefer, Robert Kleszcz, Wanda Baer-Dubowska. Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-κB and activates Nrf2 in pancreatic cancer cells. Toxicology in Vitro 2020; 65: 104799 doi: 10.1016/j.tiv.2020.104799
|
| 34 |
Joo Kyung Park, Yejin Kim, Hyemin Kim, Jane Jeon, Tae Wan Kim, Ji-Hong Park, Young-il Hwnag, Wang Jae Lee, Jae Seung Kang. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 2016; 7(46): 75081 doi: 10.18632/oncotarget.12057
|
| 35 |
Arya Nasimi Shad, Ali Fanoodi, Amirhosein Maharati, Iman Akhlaghipour, Meysam Moghbeli. Molecular mechanisms of microRNA-301a during tumor progression and metastasis. Pathology - Research and Practice 2023; 247: 154538 doi: 10.1016/j.prp.2023.154538
|
| 36 |
V Coothankandaswamy, S Cao, Y Xu, P D Prasad, P K Singh, C P Reynolds, S Yang, J Ogura, V Ganapathy, Y D Bhutia. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. British Journal of Pharmacology 2016; 173(23): 3292 doi: 10.1111/bph.13616
|
| 37 |
Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?. Asian Pacific Journal of Cancer Prevention 2015; 16(14): 5681 doi: 10.7314/APJCP.2015.16.14.5681
|
| 38 |
Wilson Petrushnko, Justin S. Gundara, Philip R. De Reuver, Greg O'Grady, Jaswinder S. Samra, Anubhav Mittal. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB 2016; 18(8): 652 doi: 10.1016/j.hpb.2016.05.004
|
| 39 |
Shreni Agrawal, Richa Das, Amit Kumar Singh, Pradeep Kumar, Praveen Kumar Shukla, Indrani Bhattacharya, Amit Kumar Tripathi, Sunil Kumar Mishra, Kavindra Nath Tiwari. Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach. Medical Oncology 2023; 40(5) doi: 10.1007/s12032-023-01996-w
|
| 40 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Kiyokazu Hiwatashi, Yota Kawasaki, Takaaki Arigami, Sumiya Ishigami, Yuko Kijima, Hiroyuki Shinchi, Sonshin Takao, Shoji Natsugoe. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Pancreatology 2015; 15(6): 688 doi: 10.1016/j.pan.2015.09.015
|
| 41 |
Dingyuan Luo, Matthew G Digiovanni, Ran Wei, Joseph F Lacomb, Jennie L Williams, Basil Rigas, Gerardo G Mackenzie. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis 2020; 41(7): 927 doi: 10.1093/carcin/bgz170
|
| 42 |
Aimin Cai, Hailun Zheng, Zhiwei Chen, Xinlu Lin, Chen Li, Qing yao, Yangzom D. Bhutia, Vadivel Ganapathy, Ruijie Chen, Longfa Kou. Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells. Biochemical Journal 2020; 477(10): 1923 doi: 10.1042/BCJ20200275
|
| 43 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Hiroyuki Shinchi, Shoji Natsugoe. Prediction of Postoperative Early Recurrence and Prognosis in Pancreatic Cancer Patients. International Surgery 2017; 102(5-6): 272 doi: 10.9738/INTSURG-D-17-00072.1
|
| 44 |
Franziska Brandes, Katharina Schmidt, Christine Wagner, Julia Redekopf, Hans Jürgen Schlitt, Edward Kenneth Geissler, Sven Arke Lang. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1064-9
|
| 45 |
Cecilia Rodriguez Lanzi, Ran Wei, Dingyuan Luo, Gerardo G. Mackenzie. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. Neoplasia 2022; 24(2): 133 doi: 10.1016/j.neo.2021.12.004
|
| 46 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Yuko Kijima, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology 2018; 25(5): 1432 doi: 10.1245/s10434-018-6357-1
|
| 47 |
Ana De Jesus-Acosta, Amol Narang, Lauren Mauro, Joseph Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology. 2020; : 1342 doi: 10.1016/B978-0-323-47674-4.00078-5
|
| 48 |
Hye-Mi Ahn, Dong-Gun Kim, Youn-Jae Kim. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells. Biochemical and Biophysical Research Communications 2020; 527(2): 568 doi: 10.1016/j.bbrc.2020.04.118
|
| 49 |
Yan Li, JinWoo Hong, Joung‐Eun Oh, A‐Rum Yoon, Chae‐Ok Yun. Potent antitumor effect of tumor microenvironment‐targeted oncolytic adenovirus against desmoplastic pancreatic cancer. International Journal of Cancer 2018; 142(2): 392 doi: 10.1002/ijc.31060
|
| 50 |
Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, Igor Bazin, Elena Poddubskaya, Nebojsa Manojlovic, Dejan Radenkovic, Chris Verslype, Eric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer 2018; 143(8): 2053 doi: 10.1002/ijc.31603
|
| 51 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Hiroyuki Shinchi, Shoji Natsugoe. Impact of p53 and PDGFR‐β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. World Journal of Surgery 2016; 40(8): 1977 doi: 10.1007/s00268-016-3477-2
|
| 52 |
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Kiyonori Tanoue, Satoshi Iino, Yota Kawasaki, Tetsuya Idichi, Takaaki Arigami, Shinichiro Mori, Yoshiaki Shinden, Michiyo Higashi, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Pancreatology 2020; 20(1): 89 doi: 10.1016/j.pan.2019.11.015
|